Blackwater Fever Treated with Steroids in Nonimmune Patient, Italy

Causes of blackwater fever, a complication of malaria treatment, are not completely clear, and immune mechanisms might be involved. Clinical management is not standardized. We describe an episode of blackwater fever in a nonimmune 12-year-old girl in Italy who was treated with steroids, resulting in a rapid clinical resolution.

The girl was admitted to the intensive care unit, where she received 4 doses of 2.4 mg/kg intravenous artesunate. Therapy was then switched to artemether/lumefantrine (80/480 mg dose, administered orally in 6 doses). Blood smears were negative for P. falciparum starting on day 4. Because the girl's hemoglobin levels had dropped steadily from the time of admission (Table), she received a blood transfusion on day 4. On day 5, she was discharged from the intensive care unit in good clinical condition and moved to the pediatric ward, where hyperchromic urine samples were observed. Empiric antibiotic treatment was started (ceftriaxone first, then piperacillin/tazobactam) to treat her persistent fever. Result of blood and urine cultures were negative, as were investigations for SARS-CoV-2 and other respiratory viruses. Chest radiographs and brain computed tomography scans (the latter performed to investigate additional causes of lethargy) had unremarkable results. Ultrasound examination revealed biliary sludge. Because the patient's hemoglobin level continued to drop, she received additional blood transfusions on days 10 and 12.
Our team suspected blackwater fever (BWF), a complication of P. falciparum infection, and colleagues from a referral center for tropical diseases confirmed the diagnosis and recommended administration of steroids. We prescribed a 5-day treatment course of oral prednisone (1.3 mg/kg), starting on day 13. We tapered off the dose over the next 15 days and administered another blood transfusion on day 16. Symptoms cleared completely the day after steroid treatment began, and urine samples became normochromic 7 days later. The patient was discharged in good clinical condition on Day 23. One month later, blood test results were unremarkable (

RESEARCH LETTERS
Causes of blackwater fever, a complication of malaria treatment, are not completely clear, and immune mechanisms might be involved. Clinical management is not standardized. We describe an episode of blackwater fever in a nonimmune 12-year-old girl in Italy who was treated with steroids, resulting in a rapid clinical resolution.

RESEARCH LETTERS
abnormal hemoglobin or glucose-6-phosphate-dehydrogenase results were noted. BWF is a condition characterized by massive hemolysis after treatment for acute malaria, with clinical symptoms that include hemoglobinuria, anemia, jaundice, and fever (1)(2)(3). The name of the syndrome relates to the presence of dark urine noted in affected patients. An apparent decrease in cases of BWF was noted when artemisinin compounds replaced quinine as first-line treatment for malaria (3,4). However, a randomized, controlled trial comparing quinine versus artesunate for treatment of severe malaria in children and found frequency of BWF did not differ significantly between the 2 study arms (p = 0.076) (5).
Artesunate has been associated with hemolytic anemia, a condition that differs from BWF in that hemolysis is delayed (usually starting from 2 to 3 weeks following initiation of artesunate therapy, although some cases can occur earlier); most important, hemoglobinuria is not reported. Another differentiating factor between the 2 conditions is that hemolysis due to artesunate is extravascular and, in BWF, hemolysis is intravascular (6).
The pathophysiologic mechanisms causing BWF are not completely understood, and no definitive evidence has emerged from investigations into the role of antimalarial drugs (mostly quinine, with some reports about halofantrine and mefloquine), characteristics of the human host (e.g., glucose-6-phosphatedehydrogenase deficiency), and parasite type (e.g., different Plasmodium strains) (1,7,8). No relationship has been reported between high levels of parasitemia and development of BWF. Because most cases of BWF arise in nonimmune persons, immune mechanisms have been suspected to cause the hemolysis (8). Nevertheless, many cases have been observed in children >5 years of age who resided in malaria-endemic areas and were suspected to carry at least partial immunity against Plasmodium spp. (8). Studies suggest that those children failed to attain protective immunity against malaria and, indeed, showed an immune profile similar to expatriates in Europe. Different mechanisms have been speculated to be involved in activating the immune response leading to BWF, including excessive complement activation and presence of a malaria immune complex antigen-antibody (8).
Treatment with steroids, as was determined for this patient, has been previously instituted in a malaria-endemic setting (9). Although evidence is not sufficient to recommend this therapeutic approach, it seems reasonable from a pathophysiologic standpoint and deserves further evaluation. Besides steroids, the 2 pillars of BWF management are blood transfusion and refraining from drugs possibly causing the syndrome (9). Because of the rarity (and neglect) of BWF (3), randomized controlled trials comparing treatment options are not currently feasible. Nonetheless, the disease is a serious consequence for children who are susceptible; there is a 3-fold higher risk of death for children with severe anemia and BWF than for children with severe anemia and no BWF (2). Considering that statistic and the poor outcomes observed in the 6 months following a BWF episode (2), evidence in support of clinical management is clearly needed.
This work was partly supported by the Italian Ministry of Health "Fondi Ricerca Corrente" to IRCCS Sacro Cuore Don Calabria Hospital-Linea 1.

About the Author
Dr Anna Rita di Biase is an MD specialist in Pediatrics and Pediatric Immunology. She is chief of the pediatric emergency unit at the University Hospital of Modena, Modena, Italy.
A 61-year-old man in Japan had multiple ulcers diagnosed on esophagogastroduodenoscopy (EGD) performed during his annual health checkup and was referred to Tokai University Hospital (Kanagawa, Japan) because of an inadequate therapeutic response. Histologic examination of tissue from the ulcer site showed inflammatory cells and few findings suggestive of malignancy. Hematoxylin and eosin staining showed spiral bacteria resembling a Helicobacter species.
Test results for H. pylori serum antibodies and stool antigen were negative. The patient had onset of epigastric discomfort after his work became busy but attributed his symptoms to his work burden and did not seek medical care. Although he had not taken nonsteroidal antiinflammatory drugs or aspirin, he did not respond to therapy, even with the administration of the antisecretory agent vonoprazan (20 mg), and had multiple refractory gastric ulcers diagnosed.
After obtaining informed consent, we enrolled the patient in a clinical trial investigating the effects of non-H. pylori Helicobacter (NHPH) infections on intractable ulcers and gastric mucosa-associated lymphoid tissue lymphoma. On August 24, 2021, we assessed the patient for NHPH by using culture and PCR of gastric biopsy samples collected during EGD (Appendix, https://wwwnc.cdc.gov/EID/ article/29/4/22-1807-App1.pdf). EGD showed no atrophy in the background gastric mucosa, healing of the ulcers observed previously, multiple erosions, and residual ulcers in the antrum (Figure, panel A). The PCR test result for NHPH was positive, but the bacterial culture result was negative. On November 30, 2021, a repeat EGD to assess ulcer healing status showed further healing. Repeat culture and PCR tests for NHPH were both positive. We isolated Helicobacter spp. strain NHP21-4376 from the greater curvature of the gastric antrum and NHP21-4377 from the lesser curvature.
Phylogenetic analysis based on 342 core genes among gastric Helicobacter species also confirmed that NHP21-4376 and NHP21-4377 are in the same clade as H. ailurogastricus strains ASB7 T and ASB9 and are distinct from H. suis strains (Appendix Figure 2). We deposited draft genome sequences of H.
We report the isolation of Helicobacter ailurogastricus, a Helicobacter species that infects cats and dogs, from a person with multiple refractory gastric ulcers. In addition to H. suis, which infects pigs, Helicobacter species that infect cats and dogs should be considered as potential gastric pathogens in humans.